{"description":"Serious Adverse Event data was not collected. Other \\[Not Including Serious\\] Adverse Events were not monitored/assessed","eventGroups":[{"deathsNumAffected":10,"deathsNumAtRisk":17,"description":"Chemo, stem cell transplantation, HLA-Matched related allogeneic stem cell transplantation, leukapheresis, G-CSF, peripheral blood stem cell transplant, fludarabine, cyclophosphamide, donor lymphocyte infusion, cyclosporine, methotrexate\n\nStem Cell Transplant: Donor: Prior to mobilization, leukapheresis to collect CD3+ cells. The donor will then receive G-CSF (10 mcg/kg/day) with leukapheresis collection of peripheral blood stem cells on days 5, 6 and 7 as needed. Goal of leukapheresis will be \\> 5 x 106 CD34+cells/kg of recipient.\n\nPatient: Peripheral Blood Stem Cell (PBSC) Transplant. Fludarabine 25mg/m2/d IV over 30 minutes on days -6 to -2, followed by cyclophosphamide 1g/m2/d IV on days -3 and -2. This will be followed by allogeneic stem cell infusion 48 hours later.\n\nDonor Lymphocyte Infusion (DLI) and Adjustment of Immunosuppression: Cyclosporine (CSA) and methotrexate (MTX) will be used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml.\n\nG-CSF: 10 mcg/k","id":"EG000","otherNumAffected":0,"otherNumAtRisk":0,"seriousNumAffected":0,"seriousNumAtRisk":0,"title":"Study Treatment"}],"frequencyThreshold":"5","timeFrame":"All-Cause Mortality was assessed for up to 15 years post-transplant. Adverse event data was not collected."}